Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage  by Keeling, John & Herrera, Guillermo A.
Kidney International, Vol. 68 (2005), pp. 1590–1603
Matrix metalloproteinases and mesangial remodeling in light
chain–related glomerular damage
JOHN KEELING and GUILLERMO A. HERRERA
Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, Louisiana; Department of Pathology,
Louisiana State University Health Sciences Center, Shreveport, Louisiana; Department of Cellular Biology and Anatomy, Louisiana
State University Health Sciences Center, Shreveport, Louisiana; and Department of Medicine, Louisiana State University Health
Sciences Center, Shreveport, Louisiana
Matrix metalloproteinases and mesangial remodeling in light
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Background. Matrix metalloproteinases (MMPs) belong to
the zinc endopeptidase subgroup of the metalloproteinase su-
perfamily and are primarily involved in extracellular matrix
(ECM) remodeling. Alterations of the mesangial ECM in
AL-amyloidosis (AL-Am) and light chain deposition disease
(LCDD) are crucial in their pathogeneses as two divergent en-
tities.
Methods. Protein expression patterns of five MMPs (MMP-1,
2, 3, 7, and 9) in renal tissues obtained from autopsies and kidney
biopsies, and cultured human mesangial cells (HMCs) treated
with light chains obtained from the urines of patients with
AL-Am and LCDD were analyzed. MMP mRNA expressions
were determined in glomeruli following laser capture microdis-
section and selective MMP microarray. Zymography was used
to assess MMP activity.
Results. The average glomerular MMP expression was 6 times
greater in AL-Am than LCDD and negative control renal tis-
sues with different expression profiles: MMP-1, 7 > 9 > 3 >
2, MMP-1 > 2, 9 > 3 > 7, and MMP-2, 3, 7 > 9 > 1, respec-
tively. Microdissected glomeruli and HMCs treated with light
chains expressed higher levels of MMP mRNA and proteins in
AL-Am than LCDD. Zymography was used to assess activity
demonstrating increased MMP-2 in AL-Am.
Conclusion. Altered expressions of MMPs play a key role
in the pathogenesis of AL-Am and LCDD. MMPs were more
highly expressed in AL-Am compared to LCDD.
Matrix metalloproteinases (MMPs) are structurally
and functionally related zinc endopeptidases belonging
to a subgroup of the much larger metalloproteinase su-
perfamily and function primarily in extracellular matrix
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(ECM) remodeling [1–4]. MMPs are ubiquitous enzymes
and more than 20 vertebrate types have been identified
to date [5]. Eight distinct structural classes of MMPs have
been designated; five classes are secreted while three are
membrane tethered [6].
All MMPs are synthesized as zymogens and are se-
creted extracellularly or transmembranely attached [7].
Their gene expressions are inducible via many mecha-
nisms and their activities may be inhibited by endogenous
specific tissue inhibitors of metalloproteinases (TIMPs),
plasminogen activation inhibitor (PAI), and other non-
specific protein inhibitors such as a2-macroglobulin [8].
Although reports on some roles of MMPs in the kidney
have been published, most have focused on the activities
of gelatinase A and B (MMP-2 and MMP-9). These high-
light the biophysical characteristics of these two closely
related MMPs and the fact that they primarily act on col-
lagen IV, the main ECM component of the mesangium.
Therefore, it is not surprising that some investigators
have reported MMP-2 to play a key role in glomerular
basement membrane (GBM) and mesangial matrix re-
modeling [9–11]. To date, little association between the
pathogenesis of renal damage due to plasma cell dyscra-
sia (multiple myeloma) and MMPs have been described.
A comprehensive array of MMP expressions in human
mesangial cells has not been delineated.
TIMPs are natural inhibitors of MMPs whose role is
paramount in their regulation. Four TIMPs have been
described and they share a 40% sequence homology [12].
However, TIMP-1 and TIMP-2 are the best described [13,
14] and likely play important roles in maintaining mesan-
gial homeostasis. Studies by Gomis-Ruth et al [15] have
revealed a unique inhibitory mechanism between the
MMPs and TIMP-1. The folding of the TIMP-1 polypep-
tide chain into a wedge-shaped molecule such that its N-
and C-terminal halves form two opposing parts blocking
the entire active cleft site of MMP-3 has been described.
Plasma cell dyscrasias, including their most dramatic
clinical expression referred to as multiple myeloma,
1590
Keeling and Herrera: MMP and mesangial remodeling 1591
are associated with the production of physicochemically
abnormal light chains, the majority of which are nephro-
toxic. Approximately 30% of the pathologic light chains
are associated with glomerular damage (also referred
to as glomerulopathic light chains), while the remaining
nephrotoxic light chains are associated with tubular in-
terstitial pathology and referred to as tubulopathic.
Renal damage has been shown to be a prominent fea-
ture of plasma cell dyscrasias resulting in renal function
disturbances [16, 17]. Just over half the number of mul-
tiple myeloma patients develop renal insufficiency and
failure, the second most common cause of death in these
patients, infections being the most common cause [17].
The interactions between glomerulopathic light chains
and mesangial cells are mediated by a yet uncharacterized
cell surface receptor and data obtained in our laboratory
indicate the presence of a single receptor providing bind-
ing sites for the different glomerulopathic light chains [18,
19].
Following interactions of the glomerulopathic light
chains with the surface receptor and internalization in
mesangial cells, a sequence of events occurs eventu-
ally leading to alterations in mesangial matrix home-
ostasis. Light chains in light chain disposition disease
(LCDD) are degraded in the early endosomes while, in
AL-amyloidosis (AL-Am) they are transported to the
mature lysosomes for processing [19]. Amyloidogenic
light chains undergo proteolysis in the mature lysosomal
compartments leading to the formation of fibrils which
are then extruded into the ECM where they accumulate
and alter the mesangial milieu.
As a consequence, two distinct characteristic patterns
of glomerular injury emerge. Fibrillary monoclonal light
chain–related renal disease, characteristic of AL-Am,
and granular deposition of immunoglobulin components
typical of LCDD constitute these patterns (Fig. 1). k
light chains are approximately two to three times more
commonly associated with AL-Am are than j [20, 21].
Solomon, Frangione, and Franklin [22] reported that kVI
light chains are more specifically associated with AL-Am
while Comenzo et al [23] demonstrated a striking tropism
of the kVI light chains for glomerular amyloidosis. Con-
versely, LCDD is usually associated with jI and jIV light
chains. Therefore, the physicochemical characteristics of
the light chains alter the behavior of mesangial cells re-
sulting in mesangial matrix alterations [24–29].
This manuscript presents evidence of variations in
MMP expressions by mesangial cells from AL-Am and
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→
(macrophage phenotype) surrounding amyloid fibrils. Mesangial nod-
ules (F to H) (hematoxylin and eosin ×400) with increased mesangial
matrix protein deposition (G) (Jones methanamine silver ×400) and
punctuate light chain deposits (H) (electron microscopy uranyl acetate
and lead citrate ×9500) in the mesangium of LCDD glomeruli.
Fig. 1. Characteristics of the AL-amyyloidosis (AL-Am) and light
chain desposition disease (LCDD) glomeruli. Replacement of mesan-
gial matrix by eosinophilic amorphous material is noted in AL-Am (A)
(hematoxylin and eosin ×400). Decreased extracelular matrix (ECM)
is demonstrated by lack of silver staining in expanded mesangial areas
(B) (Jones methanamine silver ×400), confirmation of amyloid deposits
(C) (Congo red, polarized light, (D) (Congo red, bright field ×400), and
(E) amyloid fibrils (electron microscopy uranyl acetate and lead citrate
×9500). Note transformed mesangial cells with large lysosomes
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LCDD patients at both the mRNA and protein levels.
Also, such changes were investigated in cultured human




Myeloma cast nephropathy (MCN) results from pre-
cipitation of light chains in distal tubules resulting in cast
formation. These light chains do not affect the glomerulus
and serve as a light chain control.
Negative controls are used in the analyses of glomeruli
and consist of (1) normal, which is tissue taken from
uninvolved portions of renal carcinoma nephrectomy
specimens; (2) acute tubular necrosis (ATN), which is
characterized by injury resulting in the necrosis of tubular
cells without glomerular alterations; and (3) postperfu-
sion effect (PPE), which results in proximal tubular injury
with no glomerular alterations, as consequence of renal
perfusion aimed at organ preservation prior to transplan-
tation.
Positive control used in the analysis of renal tissues
consisted of thrombotic microangiopathy (TMA) cases.
This is characterized by thrombotic occlusion of small
vessels in the renal vasculature resulting in mesangiolysis
and, at times, overt glomerular necrosis associated with
the activation of metalloproteinases.
Isolation of HMCs
HMCs were obtained from unused kidney tissue that
was earmarked for transplantation, or from normal ar-
eas of nephrectomy tissue removed for neoplastic condi-
tions. The cortices from these kidneys were minced and
pressed onto sterile stainless steel sieves of various pore
diameters (315, 250, and 180 lm) as previously described
[30]. Whole glomeruli retained on the 180 lm sieve were
collected then washed in Hank’s buffered saline solution
(HBSS) and centrifuged. The glomerular pellets were re-
suspended in Hepes-buffered HBSS (pH 7.4) contain-
ing 750 lg/mL collagenase IV (Sigma Chemical Co.,
St. Louis, MO, USA). After 30 minutes incubation
with gentle agitation, the suspension was centrifuged
at 1000 rpm for 10 minutes. The pellets were washed
twice and resuspended in complete medium containing
RPMI 1640 (Life Technologies-Gibco, Grand Island, NY,
USA), buffered with 12.5 mmol/L Hepes (Sigma Chemi-
cal Company), supplemented with heat inactivated 20%
fetal calf serum (FCS) (Life Technologies), penicillin
100 U/mL, streptomycin 100 lg/mL 5 lg/mL bovine in-
sulin, 2 mmol/L glutamine, 5 lg/mL transferrin, 5 lg/mL
selenite, and 1 mmol/L sodium pyruvate (all from Sigma
Chemical Co.), and plated onto 100 lm2 tissue culture
dishes.
The glomerular cells were carefully assessed for 3 to 5
days. Once outgrowths were established, the cells were
trypsinized, passed through a 75 lm sieve to remove the
whole glomeruli, and replated on tissue culture dishes.
The cells were maintained at 37◦C in a humidified incu-
bator containing 5% CO2. Mesangial cells overgrew ep-
ithelial cells and became confluent 3 to 4 weeks after plat-
ing. Cells were then trypsinized and transferred to 8-well
chambered slides. Ultrastructural examination and im-
munohistochemical staining positive for muscle-specific
actin and vimentin, and negative for keratin and factor
VIII, confirmed the presence of a homogeneous popula-
tion of mesangial cells. These mesangial cells were then
frozen at −70◦C and passaged for future experiments.
Isolation and purification of light chains
Free light chains were purified from the urine of pa-
tients with known LCDD or AL-Am or MCN, used
as a tubulopathic light chain control, which has been
proven not to interact with mesangial cell receptors and
do not alter transforming growth factor b (TGF-b) [31,
32] by a series of affinity chromatography steps. Urine
was passed over an affinity column comprised of either
goat anti-human j or k light chain antibody conjugated
to sepharose CL-4B. Free and bound light chains were
eluted from the column with 0.1 mol/L glycine, pH 2.2.
The purity of the light chains were assessed on immun-
odiffusion plates and contaminating proteins (IgG and
IgA) were removed by subsequent repeated passages
over affinity columns to which either antihuman IgG or
IgA antibodies were conjugated.
Purified light chains migrated as a single band when
resolved by zone electrophoresis on agarose gels using a
50 mmol/L barbital buffer, pH 8.6, and consisted entirely
of either free j or k protein as determined by immunofix-
ation. The purified light chain was then concentrated,
dialyzed against 0.9% NaCl, filtered through a sterile
0.2 lm membrane, and stored aseptically in sealed vials
at 4◦C. Purified light chains from individual patients were
used for each of the experiments. Light chains were not
pooled by categories for the experiments.
Incubation of HMCs with light chains
HMCs of third passage were thawed from stocks of
harvested cells previously described. These cells were
seeded onto 8-well tissue culture glass slides and 1002
mm Petri dishes in modified RPMI 1640 culture medium.
RPMI 1640 containing 12.5 mmol/L Hepes, 2 mmol/L
L-glutamine and phenol red (Sigma Chemical Co.) was
supplemented with heat inactivated 15% fetal bovine
serum (FBS) (Pierce Biotechnology, Inc., Rockford, IL,
USA), penicillin 100 U/mL, streptomycin 100 lg/mL,
ITS (bovine insulin 5 lg/mL, 5 lg/mL transferrin, and 5
lg/mL selenite), and 1 mmol/L sodium pyruvate (Sigma
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Chemical Co.). They were allowed to grow to approxi-
mately 90% confluence with media change every 3 days
after which they were brought to quiescence for 48 hours
with the same culture medium now containing 0.5% FBS.
Duplicate cultures were incubated with a MCN light
chain, a LCDD light chain or an AL-Am light chain di-
luted (10 lg/mL) in phenol red free RPMI 1640 contain-
ing 12.5 mmol/L Hepes, 2 mmol/L L-glutamine, penicillin
100 U/mL, streptomycin 100 lg/mL, ITS, 1 mmol/L
sodium pyruvate, and 0.5% FBS. HMCs in culture
medium devoid of light chains served as control. Cells
were incubated for up to 96 hours at 37◦C and 5%
CO2 for 96 hours. Cells and supernatants were har-
vested at different time intervals (12, 24, 48, 72, or
96 hours). Some cells grown in Petri dishes were har-
vested at 96 hours. Cells and treated with TRIzol
Reagent (Invitrogen Life Technologies, Carslsbad, CA,
USA) to obtain RNA and proteins. Conditioned media
harvested at different time points were further processed
for protein analysis by Western blotting. HMCs grown
on 8-well tissue glass slides were harvested at 96 hours,
rinsed twice with phosphate-buffered saline (PBS), pH
7.4, then fixed in 95% ethanol for 45 minutes. Slides were
then stored at −20◦C for future immunohistochemical
analyses.
Experimental controls
Controls used in the in vitro experiments consisted of
HMCs incubated without light chains in phenol red free
RPMI 1640 containing 0.5% FBS. Controls in the renal
tissue experiments consisted of tissue taken from unin-
volved portions of renal carcinoma nephrectomy speci-
mens, serving as negative controls, and glomeruli affected
by TMA serving as positive controls. MCN-light chains
were employed as an internal nonglomerulopathic light
chain control to compare with the glomerulopathic light
chains of interest.
Preparation of conditioned media from in vitro
experiments
Conditioned media from the in vitro experiments were
harvested then concentrated by centrifugation using 10K
Macrosep centrifugal devices (Pall Corporation, Ann
Arbor, MI, USA) which were centrifuged at 2390 × g for
35 minutes at 4◦C. The concentrated conditioned media
were then collected in 2 mL microcentrifuge tubes and
stored at −70◦C until needed.
RNA and protein isolation from HMCs using TRIzol
Reagent
Total RNA and proteins were isolated from cultured
HMCs incubated with light chains or culture media (de-
scribed above) using TRIzol Reagent (Invitrogen Life
Technologies). RNA samples were stored at −70◦C for
future analysis. The protein concentrations were deter-
mined prior to Western blotting or enzyme-linked im-
munosorbent assay (ELISA) analyses.
Western blot on HMC-conditioned media
Conditioned media harvested from cultured HMCs
treated with light chains were diluted in 4× lithium
dodecyl sulfate (LDS) buffer (Invitrogen Life Tech-
nologies) to contain 90 lg total proteins in 37
lL. Unknown samples, standards [10 lL recombi-
nant human MMP (R&D Systems, Minneapolis, MN,
USA)] and molecular marker were loaded onto
NuPAGE Novex 4% to 12% Bis-Tris (1.5 mm, 10 wells)
gels (Invitrogen Life Technologies) and electrophoresed.
The gels were later transferred onto polyvinylidine diflu-
oride (PVDF) membranes by electrophoresis.
Twenty milliliters diluted anti-MMPs 1, 2, 3, 7, and
9 antibodies (R&D Systems) diluted to 1 lg/mL was
added to the respective membranes and incubated at
4◦C overnight. The membranes were then washed with
Tris-buffered saline containing 0.05% Tween-20 (TTBS)
at room temperature and agitation then probed with
20 mL goat antimouse horseradish peroxidase (HRP)–
conjugated (Jackson Laboratory, Bar Harbor, ME, USA)
secondary antibody diluted 1:20000 with diluent buffer
for 1 hour at room temperature. The membranes were
then washed four times with TTBS for 10 minutes each
at room temperature and agitation.
Membranes were placed in Pierce Dura Signal (Pierce
Chemical) detection reagent for 5 minutes at room
temperature with agitation. X-ray films were used to
capture images which were later analyzed. Mean density
values the protein bands were performed by densitome-
try on a Kodak Image Station 2000mm using Kodak Dig-
ital ScienceTM one-dimensional image analysis software
(Rochester, NY, USA).
Zymography on conditioned media
Conditioned media from cultured HMCs treated with
light chains were harvested at 12 hours, 48 hours, and
96 hours. These were diluted to contain 15 lg total pro-
teins in 20 lL. Samples, recombinant human MMP-2
(2.5 ng/lL) and recombinant human MMP-9 (5.0 ng/lL)
(R&D Systems) controls were further diluted in a similar
volume of 2× Novex Tris-glycine sodium dodecyl sul-
fate (SDS) sample buffer (Invitrogen Life Technologies).
Twenty microliters of samples and controls were loaded
onto Novex zymogram (1.5 mm, 15 wells) gels (Invit-
rogen Life Technologies) and electrophoresed at 125 V
constant for 90 minutes in Novex Tris-glycine SDS run-
ning buffer (Invitrogen Life Technologies). After elec-
trophoresis, the gels were removed and incubated in two
changes of zymogram renaturing buffer (Invitrogen Life
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Technologies) for 30 minutes at room temperature with
gentle agitation. Gels were then washed in zymogram
developing buffer (Invitrogen Life Technologies) then
incubated in fresh developing buffer at 37◦C overnight
with gentle agitation. The gels were rinsed in distilled
water then placed in Bio-SafeTM coomassie (Bio-Rad
Laboratories, Hercules, CA, USA) for 40 minutes at
room temperature and gentle agitation. They were then
washed in three changes of distilled water for 20 min-
utes each. Gels were photographed and analyzed using a
Kodak Image Station 2000mm and Kodak Digital Sci-
enceTM one-dimensional image analysis software.
Immunohistochemical analysis of MMPs, collagen IV,
and tenascin
Sixty-one formalin-fixed and paraffin-embedded kid-
ney tissues from autopsy and renal biopsies from patients
with different diagnoses (LCDD = 12, AL-Am = 10, neg-
ative controls=31, and TMA=8), were sectioned at 5 lm
thick. Additionally, 46 cases were selected from the cases
mentioned (LCDD = 3, AL-Am = 9, negative controls
= 29, and TMA = 5) for collagen IV and tenascin in-
vestigations. Sections were deparaffinized, hydrated, and
antigen retrieval performed on them using moist heat by
placing them in preheated 0.01 mol/L sodium citrate (pH
6.0) and further heating at 100◦C for 25 minutes [33].
Endogenous peroxidase activity in the tissue sections
and HMCs from the in vitro experiments was blocked
by incubating them with DAKO Peroxidase Blocking
Reagent (Dako Cytomation, Carpinteria, CA, USA) con-
taining H2O2 for 5 minutes. Slides were then rinsed three
times with PBS (pH 7.4) and blocked with DAKO Pro-
tein Block Serum-Free (Dako Cytomation) containing
0.25% casein in PBS containing carrier protein and NaN3
for 5 minutes at room temperature. TTBS was used to
rinse slides three times prior to the addition of the pri-
mary monoclonal antibodies. A total of 150 lL of diluted
anti-MMPs 1, 2, 3, 7, and 9 (1:20 dilutions of 200 lg/mL
stock) (R&D Systems) and collagen IV, 1:40 dilution
(2.5 lg/mL) and tenascin-C, 1:40 dilution (14 lg/mL),
were added to the slides. The slides were incubated at 4◦C
overnight, and then rinsed three times with TTBS. A total
of 150 lL of peroxidase-labeled polymer (Dako Cytoma-
tion) was added to each slide and incubated for 30 min-
utes at room temperature. Sections were carefully rinsed
three times with TTBS and drained. Slides were treated
with chromagen substrate containing diaminobenzidine
(DAB) then incubated at room temperature for 7 min-
utes. Slides were rinsed three times in distilled water fol-
lowed by counterstaining with Harris’ hematoxylin for
10 seconds at room temperature. They were then placed
in running tap water for 30 minutes. Sections were finally
dehydrated through ascending concentrations of ethanol,
cleared in xylene, then mounted with permount.
Grading of immunohistochemical staining
Immunohistochemical staining was assessed based on
the presence or absence of brown coloration in the cells
denoted as positive or negative, respectively. Staining was
graded on a numerical scale of 0 to 4, where 0 represented
no staining (negative), and 1 to 4 represented positive
staining (1 being the least intense and 4 being the most
intense staining). Brown staining intensity was assessed
by comparison with the staining intensity of the nuclei
present in the samples, and grading reflected the strongest
staining intensity noted in the sample. Grading was con-
ducted by two investigators independently and without
knowledge of sample category.
Protein and RNA isolation following laser capture
microdissection (LCM)
LCM technique was used to obtain intact glomeruli
from formalin-fixed paraffin-embedded tissues. Two sam-
ples were selected from each of five specimen categories:
ATN, AL-Am, negative controls, LCDD, and TMA. Two
caps were used to harvest approximately 120 glomeruli
each. One was used for protein and the other for RNA
analyses. The caps earmarked for protein determina-
tion were inserted onto microcentrifuge tubes containing
50 lL T-PERTM tissue protein extraction reagent, in-
verted, and incubated for 30 minutes at room temper-
ature. Samples were centrifuged at 10,000 rpm for 5 min-
utes and the supernatants collected. These were analyzed
for MMPs 1, 2, 3, 7, and 9 proteins using Quantikine
ELISA assays (R&D Systems).
Quantikine ELISA assay for MMP proteins
Supernatants obtained from LCM glomeruli were ana-
lyzed for MMP protein expressions using an ELISA tech-
nique. For normalization purposes, each sample was di-
luted to contain 1 lg of total protein. Kits were obtained
for MMPs 1, 2, 3, 7, and 9 (R&D Systems). All reagents,
working standards and samples were prepared in accor-
dance with the manufacturer’s protocol. A total of 100
lL of assay diluent was added to each well of the sup-
plied 96-well microtiter plate. Fifty microliters or 100 lL
standard or sample was added to each well (depending
on the requirements of the protocol for each MMP) and
incubated for 2 hours at room temperature on a horizon-
tal orbital microplate shaker at 500 rpm. The contents
of each well were aspirated then the wells were washed
four times with wash buffer. Then, 200 lL conjugate was
added to each well prior to incubating for 2 hours at room
temperature on the shaker. The contents of each well was
aspirated and washed four times with wash buffer then
200 lL substrate solution was added to each well. Plates
were incubated for 20 or 30 minutes (depending on pro-
tocol) at room temperature in the dark. Finally, 50 lL
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stop solution was added to each well and the absorbance
at 450 nm and 540 nm for k correction obtained
RNA analysis using microarray technology
Total RNA isolated from treated HMCs (in vitro ex-
periments) and laser-captured microdissected glomeruli
were assessed for MMP and TIMP mRNA. Sample vol-
umes were adjusted to contain a total RNA concentration
of 1 lg (cultured HMCs) and 3 lg (glomeruli) in 18 lL
with RNase-free H2O. A selective MMP/TIMP Non-Rad
Ampo-Labeling GEArray Original Series (SuperArray,
Fredrick, MD, USA) microarray technique was employed
in measuring mRNA concentrations in these samples ad-
hering to manufacturer’s instructions. The results of the
experiments were obtained from membranes provided
with the kits which were scanned then converted and
saved as gray scale TIFF files. These were later analyzed
using a ScanAlyze (Dr. Michael Eisen, Stanford Uni-
versity, California) software to identify and determine
mRNA expressions of MMPs and TIMPs.
Statistical analysis
Statistical analysis of the results, where stated, was con-
ducted using the Wilcoxon sum ranked test for nonpara-
metric two-way analysis of variance (ANOVA) at a con-
fidence interval of P < 0.05.
RESULTS
MMP expressions in cultured HMCs by Western blot
Conditioned media from HMCs treated with light
chains were harvested at 72 and 96 hours and probed
for MMPs 1, 2, 3, 7, and 9 using Western blots. Bands
shown in Figure 2A were observed to be more intense
the supernatant of the AL-Am-light chain–treated cells
compared to the LCDD-light chain cells. Densitometry
confirmed these findings and revealed higher MMP levels
present in the conditioned media of AL-Am-light chain–
treated HMCs than in those treated with LCDD-light
chains. There were statistical significantly higher protein
expressions of MMP-1 (×3.4) and MMP-7 (×3.6) at 72
hours and MMP-1 (×3.7), MMP-7 (×1.6) and MMP-9
(×5.3) at 96 hours by HMCs treated with AL-Am-light
chains compared those treated with LCDD-light chains
(Fig. 2B).
Zymography on conditioned media
Zymograms were performed on conditioned media
from HMCs treated with light chains were harvested at 12
hours, 48 hours, and 96 hours. Bands migrating at 60 kD
in the test samples and the recombinant human MMP-2
(rhMMP-2) controls were noted. These digestion bands
were considered to be MMP-2. Data analysis revealed
that MMP-2 levels were significantly higher in the me-
dia from AL-Am-light chain–treated cells compared to
LCDD-light chain–treated cells and control (Fig. 3). Only
the AL-Am-light chain supernatant resulted in values
which were greater than control.
Immunohistochemical analysis of HMCs post-light chain
treatment
MMP protein expression was analyzed in the HMCs
incubated with light chains (Fig. 4). Cells harvested at 96
hours of incubation showed intracellular expression of
only MMP-7. Control cells showed no intracellular MMP
expressions.
Immunohistochemical analysis of MMP expression in
glomeruli and all renal compartments
MMP protein expressions in all renal compartments
were quantitated; however, glomerular expressions were
the main focus. These proteins were expressed differently
in the glomeruli (Fig. 5A) with statistically higher expres-
sion levels (6.4 times) in AL-Am glomeruli compared to
those in LCDD cases (Fig. 5B). Significant differences in
the average total MMP expressed in all renal compart-
ments by the AL-Am and LCDD cases (Fig. 5B). No sta-
tistical significant differences were observed between the
negative (PPE, normal, and ATN) and LCDD cases. Simi-
larly, no difference was noted between AL-Am and TMA
(positive control) cases. The results presented in Figure
5 are the averages of MMPs 1, 2, 3, 7, and 9 in both the
glomeruli and all renal compartments (glomeruli, tubular
interstitium, and vasculature) for each disease category.
Collagen IV and tenascin expression in glomeruli
Collagen IV and tenascin protein expressions in
glomeruli were analyzed (Fig. 6A). Significant differences
were noted in tenascin protein expressions among the
AL-Am and LCDD cases (Fig. 6B). LCDD cases ex-
pressed three times more tenascin and two times more
collagen IV than the AL-Am cases. However, both AL-
Am and LCDD glomeruli showed decreased levels of
collagen IV compared to the negative controls.
MMP protein expressions in LCM glomeruli
using ELISA
MMP proteins in LCM glomeruli were analyzed us-
ing an ELISA technique. Data showed increased MMP
expressions in AL-Am glomeruli compared to LCDD
cases. Statistically significant differences in MMPs 1, 2,
and 7 were noted between the two groups compared. Sig-
nificant differences were also noted in MMPs 1, 2, and
3 between AL-Am and negative cases. MMP-2 was the
most highly expressed of the MMPs in all test categories
(Fig. 7). The patterns of expression already identified in
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Fig. 2. Matrix metalloproteinase (MMP) ex-
pression. (A) Conditioned media from hu-
man mesangial cells (HMCs) treated with
light chains by Western blots. Samples were
obtained after 72- and 96-hour incubations.
Abbreviations are: control, no light chain;
MCN-LC, myeloma cast nephropathy tubu-
lopathic light chain; LCDD-LC, light chain
deposition disease light chain; AL-Am-LC,
AL-amyloidosis light chains. Note higher in-
tensities of almost all band from AL-Am-light
chain media compared to LCDD and con-
trols. (B) MMP protein expression in con-
ditioned media from cultured HMCs with
light chains using densitometry after Western
blot. Expression values (arbitrary units) of the
samples are shown compared to control (0
line). Note statistical significantly higher pro-
tein expressions of MMP-1 and MMP-7 at 72
hours and MMP-1, MMP-7, and MMP-9 at
96 hours by HMCs treated with AL-Am-light
chains compared those treated with LCDD-
light chains.
the immunohistochemically stained paraffin embedded
samples were recapitulated in these studies.
MMP and TIMP mRNA expressions in LCM glomeruli
using ELISA
The glomeruli obtained from the LCM samples were
analyzed for their MMP mRNA expressions. Statistically
significant differences (six times more) were noted be-
tween the AL-Am and LCDD cases for all the MMPs,
and, notably MMP-7 which was markedly decreased in
the LCDD glomeruli (Fig. 8). TIMP-1 mRNA expression
was less than TIMP-2. Overall, data indicates that MMP
and TIMP mRNAs were inversely proportional to each
other especially in the case of AL-Am. Values shown are
normalized to those obtained for the negative control as
shown by the “0” line.
MMP and TIMP mRNA expressions in HMCs incubated
with lCS using ELISA
Analysis of the in vitro HMCs reported data showed
MMP-2, MMP-3, and MMP-7 to be more highly ex-
pressed statistically in AL-Am–treated cells than LCDD-
treated cells (Fig. 9). Data from other time points (not
shown) gave similar results. TIMP-2 mRNA was also
noted to be significantly higher than TIMP-1. Test results
were referenced against normal values (0 line).
CONCLUSION
MMPs are a group of ubiquitous enzymes with a
diverse repertoire of proteolytic activities, including
the activation of other MMPs through cleavage their
prodomains. Expression of MMPs by mesangial cells can
be altered by a variety of conditions. Glomerulopathic
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Fig. 3. Analysis of zymograms for matrix
metalloproteinase (MMP) activity on 10%
gelatin gels. More intense digestion bands
were observed in the conditioned media from
the Al-amyloidosis-light chains (AL-Am-
LC)–treated human mesangial cells (HMCs)
compared to the light chain desposition dis-
ease (LCDD)-light chains and control (0
line). The AL-Am bands exhibited signifi-
cantly higher intensity values above the con-
trol while the LCDD-light chain bands inten-
sities were lower than control.
light chains from patients with plasma cell dyscrasias are
associated with two well-defined clinicopathologic enti-
ties: LCDD and AL-Am which alter mesangial home-
ostasis through divergent avenues. Mesangial matrix
accumulation occurs in LCDD driven by activation of
TGF-b [34], while ECM replacement is consistent with
AL-Am. Interestingly, TGF-b is decreased in the latter
[31]. The present translational study defines the role that
MMPs play in these conditions and correlate tissue find-
ings with in vitro data in an effort to elucidate the patho-
genesis of these conditions.
Mesangial cells are crucial in the pathogenesis of both
above-mentioned conditions associated with plasma cell
dyscrasias. Mesangial cells are embedded in the mesan-
gial matrix and control its turnover by maintaining equi-
librium between synthesis and degradation of matrix
components. They also generate the excess ECM rich in
tenascin present in the mesangial nodules seen in LCDD
[34]. Renal amyloidosis begins in the mesangium and
mesangial cells play a fundamental role in the forma-
tion of amyloid fibrils and eventual replacement of the
native mesangial matrix (Fig. 10). While the mechanisms
involved in matrix replacement are not well understood,
mesangial cell behavior is modulated by ECM compo-
nents [13, 35, 36]. Relatively, phenotypic transformations
occurring in these cells in relation to light chain type
(AL-Am or LCDD) may also have a role in the over-
all response glomerular response to injury [37].
Due to the complexities and dynamism of HMCs and
ECM behavior, coupled with the undefined roles of
MMPs and TIMPs, this study was designed to investi-
gate the behavior of HMCs in vitro. A comparison of
these events with the glomerulopathic manifestations of
AL-Am and LCDD could provide a basis for a
translational approach to the understanding of their
pathogeneses.
The role of MMPs and TIMPs in renal diseases has
been addressed by relatively few studies [10, 11, 38, 39].
Most of these studies have investigated MMPs 2 and 9
(gelatinases) which engage predominantly in the degra-
dation of collagen IV, the most important native ECM
protein in the mesangium. MMP-2 (gelatinase A) has
been shown to regulate glomerular mesangial cell pro-
liferation and differentiation [10] and play an important
role in renal tubular epithelial-mesenchymal transforma-
tion [40]. The current availability of MMP-deficient mice
has provided a new platform to further study the role of
MMPs in glomerular homeostasis [41].
Two studies have addressed MMPs and TIMPs in amy-
loidosis [42, 43]. The first study analyzed the distribution
of MMPs 1, 2, 3, and 9 and TIMPs in generalized amy-
loid A protein-associated amyloidosis (AA) and AL-Am
in autopsy material [42]. Only MMPs 1, 2, and 3 were
present in AA-amyloid deposits and only TIMP-1 and
TIMP-2 (no MMPs) were noted in AL-amyloid deposits.
The authors hypothesized that MMPs participate in amy-
loidogenesis either by processing the precursor protein
serum amyloid-A (SAA), by degrading amyloid deposits,
or by remodeling the interstitial matrix after amyloid de-
position. The authors also concluded that since no MMPs
were associated with AL-amyloid deposits, it was unlikely
that the presence of MMPs was important for tissue re-
modeling in this type of amyloidosis. In the second study,
amyloid degradation by MMPs 1, 2, and 3 was tested and
the three MMPs were able to cleave SAA and amyloid
fibril proteins [43]. The authors claimed this to be the first
study to show that human SAA and amyloid fibril pro-
teins are susceptible to proteolytic cleavage by MMPs.
Similar studies were not conducted with AL-amyloid.
MMPs 1, 2, 3, 7, and 9 were selected for analysis in
the present study. These MMPs are representative of the
entire spectrum of MMPs in terms of their composition
and respective catalytic capabilities with the exception
of membrane-associated MMPs (MT-MMPs) which were
not studied [44]. Also, reliable commercial antibodies to
these MMPs were available, which is not the case for
all MMPs. Expression of the above mentioned MMPs
and TIMPs was determined in glomeruli and total renal
parenchyma in tissue samples. Total renal parenchymal
MMPs and TIMPs determination was performed to gain





MMP-1 MMP-2 MMP-3 MMP-7 MMP-9
Fig. 4. Matrix metalloproteinase (MMP) ex-
pressions in human mesangial cells (HMCs)
incubated with light chains. Cells were har-
vested at 96 hours’ incubation. Note only
MMP-7 was identified in HMCs. Abbrevia-
tions are: MCN, myeloma cast nephropathy;
LCDD, light chain disposition disease; AL-
Am, AL-amyloidosis. Immunohistochemistry






MMP-1 MMP-2 MMP-3 MMP-7 MMP-9A
Fig. 5. Matrix metalloproteinase (MMP) ex-
pression patterns in renal glomeruli. (A)
Different categories of light chain–mediated
glomerular injury. Note significant increase in
expression of all MMPs in AL-amyloidosis
(AL-Am) and in thrombotic microangiopa-
thy (TMA) (positive control). LCDD is light
chain disposition disease. Immunohistochem-
istry [diaminebenzidine (DAB) as chroma-
gen) ×400. (B) Average glomerular and to-
tal (all renal compartments) expressions of
MMPs in renal tissue by manual grading. Note
the statistical significant differences between
the AL-Am, LCDD, and the negative controls
in glomerular (∗) and all renal compartments
(#).
a better understanding of the comprehensive activities of
these molecules on renal homeostasis, in spite of the fact
that this study was focused on glomerular alterations. In-
deed, overall MMP expressions were markedly increased
in renal tissues from patients with AL-Am when com-
pared with negative controls and cases with LCDD.
The study primarily encompassed glomerular determi-
nation of MMPs and TIMPs expression using immuno-
histochemistry, protein quantification by ELISA tech-
niques, and mRNA levels using a selective microarray
for MMPs and TIMPs. LCM was employed to selec-
tively obtain glomeruli from 12 patient samples, including
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Fig. 6. Collagen IV and tenascin expression patterns in renal glomeruli.
(A) Different categories of light chain–mediated injury and controls.
Note higher expressions of collagen IV in light chain disposition disease
(LCDD) and negative glomeruli, and the presence of tenascin proteins
only in the LCDD glomerulus. Immunohistochemistry [diamineben-
zidine (DAB) as chromagen] ×400. (B) Analysis of collagen IV and
tenascin expressions in glomeruli. Note the significant difference (×3)
in tenascin expression in LCDD when compared to AL-amyloidosis
(AL-Am) glomeruli. Collagen IV was detected in lower quantities in
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renal biopsies and autopsy specimens, from patients with
LCDD and AL-Am. MMP and TIMP protein and mRNA
levels were also assessed and in human mesangial cells
incubated with light chains purified from the urine of pa-
tients with LCCD and AL-Am. A marked increase in
MMP glomerular expressions in kidney specimens from
patients with AL-Am compared with normal kidneys was
noted with MMPs 1 and 7, revealing an eightfold in-
crease and a 2.3-fold increase for MMP-2. There were no
detectable intracellular expressions of MMPs in HMCs
incubated with glomerulopathic light chains by im-
munohistochemistry, except for MMP-7. The cytoplasmic
expression of MMP-7 was considered significant as the
concentrated intracellular localization of any MMP was
not expected. Previous attempts to detect MMP proteins
in cell lysates were unsuccessful, while the proteins were
abundantly found in the conditioned media, indicating
that MMPs were secreted rapidly into the media. The
presence of MMP-7 in intracellular vesicles suggests a de-
fect in the release of this particular MMP into the ECM.
This fact may be of significance in the pathogenesis of
these disorders and may explain the tenascin-rich matrix
that is typically noted in LCDD.
There were no significant differences in glomerular
TIMP expressions in the two diseases when compared
with control samples. There was, however, a significant
decrease in TIMP-2 mRNA when compared with TIMP-1
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NEG LCDD AL-Am TMA
Fig. 7. Matrix metalloproteinase (MMP) ex-
pression in microdissected glomeruli. Note
increased expression of all MMPs in AL-
amyloidosis (AL-Am) cases compared to light
chain disposition disease (LCDD) cases with
significant differences (∗) in MMPs 1, 2, and
7. Also, MMP-7 was the most inhibited MMP
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Fig. 8. Matrix metalloproteinase (MMP)
and tissue inhibitor of metalloproteinase
(TIMP) mRNA expression in microdissected
glomeruli compared to negative control
(0 line). All MMPs showed statistically
significant increased expression levels in
AL-amyloidosis (AL-Am) compared light
chain disposition disease (LCDD) glomeruli.
Note also, in almost all categories, while
MMP expression was increased, TIMP
expression was inhibited, especially in the
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Fig. 9. Matrix metalloproteinase (MMP)
and tissue inhibitor of metalloproteinase
(TIMP) mRNA expressions in light chain–
treated human mesangial cells (HMCs)
compared to control (0 line). HMCs har-
vested at 24 hours’ incubation showed MMPs
2, 3, and 7 to be significantly more highly
expressed in AL-amyloidosis (AL-Am) than
light chain disposition disease (LCDD).
TIMP-2 mRNA was also noted to be signifi-
cantly higher than TIMP-1. Test results were
referenced against normal values.
mRNA in microdissected glomeruli. Zymography was
then used to confirm increased MMP-2 activity in AL-Am
when compared with LCDD and normal. This finding in-
dicates higher levels of active MMP-2 in the conditioned
media of AL-Am-light chain–treated HMCs compared
to LCDD-light chain cells.
Another striking finding was a marked reduction in
MMP-7 in HMCs incubated with LCDD-light chain.
Tenascin is known to be catabolized predominantly by
MMP-7 and to a much lesser extent by MMP-3 and MMP-
1 [47]. Tenascin is an ECM protein that is a compo-
nent of the mesangium in normal and, most important,









Fig. 10. Interactions between mesangial cells and glomerulopathic light chains and mesangial matrix alterations. Light chain disposition disease-light
chains (LCDD-LC) interact with surface receptors on cells and are metabolized in the early endosomes. AL-amyloidosis-light chains (AL-Am-LCs)
are endocytosed avidly and processed in the mature lysosomes, resulting in opposing transforming growth factor-b (TGF-b), extracellular matrix
(ECM), and matrix metalloproteinase (MMP) alterations. MMP secretion and expression are increased by human mesangial cells (HMCs) in
AL-Am while decreased in LCDD HMCs. HMCs incubated with LCDD-light chains acquire a well-developed rough endoplasmic reticular system
transforming into myofibroblasts, while HMCs incubated with amyloidogenic light chains transform into a macrophage phenotype, acquiring
numerous lysosomes and losing their normal smooth muscle features.
pathologic conditions [48, 49]. It has been shown to accu-
mulate in a variety of conditions resulting in irreversible
functional consequences [50–52]. It has been demon-
strated that there are a number of spliced tenascin vari-
ants [53–55], some very resistant to catabolism. Tenascin
is known to accumulate in the center of mesangial nodules
in patients with LCDD and nodular glomerulosclerosis
and is also found in the mesangial matrix that remains in
AL-Am [35]. Tenascin production by mesangial cells is
enhanced in the in vitro model [18] as well as in patients
with LCDD. The increased tenascin production and in-
hibited expressions of MMPs 7 and 3 combine to provide
a clear understanding of the mechanisms at play in the
alterations of mesangial matrix that occur in LCDD.
The results in this study indicate good correlation be-
tween in vitro and in vivo models for MMP and TIMP
expression. It was demonstrated that human mesan-
gial cells incubated with light chains from patients with
AL-Am up-regulate MMP mRNA synthesis without
concommittal up-regulation of TIMP mRNA synthe-
sis. However, in LCDD-light chain–treated cells, MMP
mRNA was down-regulated with no significant changes
in TIMP mRNA synthesis. These in vitro results par-
alleled those from the microdissected glomeruli. The
results observed in the in vitro system provided experi-
mental support for MMP and TIMP alterations that have
been documented to occur in LCDD and AL-Am [56].
Also, these findings provide evidence of the pathogene-
sis of these two glomerulopathies. The overproduction of
MMPs with no increased inhibition of TIMPs results in
the accelerated destruction of the mesangial matrix seen
in AL-Am, while the inhibition of MMPs with normal
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TIMPs production allows for the increased accumulation
of matrix proteins seen in LCDD.
Evidence for the latter is further borne out in the data
obtained from the analysis of collagen IV and tenascin
in these glomeruli. The expressions of both proteins
were noted to be increased in LCDD glomeruli with
significant increased expression of tenascin compared
to AL-Am glomeruli. The data obtained in the studies
where HMCs were incubated on different matrices (data
not shown) [abstracts; Keeling J and Herrera GA, Mod
Pathol 18:267A, 2005; Lab Invest 85:267A, 2005] demon-
strated further enhancement of the deleterious effects of
the LCDD-light chains with incremental mesangial ma-
trix protein production especially collagen I and tenascin.
Collagen I is not present in the normal mesangial matrix.
In LCDD the initial inhibition of MMP-7 promote the
accumulation of tenascin in the mesangial matrix, poten-
tiating further matrix increase. In contrast, overexpres-
sion of virtually all MMP proteins occurred when HMCs
were incubated in the various matrices.
There are particular physicochemical characteristics of
some light chains that make them prone to be associ-
ated with LCDD or AL-Am [24–29]. These peculiarities
in the amino acid composition and the conformation of
such light chains have been shown to play a key role in
determining how they will affect function of mesangial
cells and eventually alter mesangial homeostasis [21–29].
There may also be other factors, including host factors,
which may also contribute to the propensity of a given
light chain to affect mesangial cell function in a specific
manner [57].
In summary, the present study depicts crucial
pathogenic mechanisms involved in mesangial alterations
that occur in LCDD and AL-Am. The study provides a
platform for additional studies dealing with possible ther-
apeutic interventions that would help stop, ameliorate or
reverse adverse irreversible consequences arising from
glomerulopathic mesangial cell interactions responsible
for the pathologic consequences that occur in these dis-
orders.
ACKNOWLEDGMENTS
We wish to thank Dr. Luan Truong and Dr. Lija Joseph for their
support in the procurement of specimens. Thanks also to Dr. Kevin
McCarthy and Mrs. Lory Tubbs (graphic designer) for their assistance.
Reprint requests to Guillermo A. Herrera, M.D., Department of
Pathology, Louisiana State University Health Sciences Center, Shreve-
port, 1501 Kings Highway, Shreveport, LA 71130.
E-mail: gherre@lsuhsc.edu
REFERENCES
1. PARKS WC: Matrix metalloproteinases in repair. Wound Rep Reg
7:423–432, 1999
2. THIENNU H, VU ZW: Matrix metalloproteinases: Effectors of devel-
opment and normal physiology. Genes Development 14:2123–2133,
2000
3. GAIRE M, MAGBANUA Z, MCDONNELL S, et al: Structure and expres-
sion of the human gene for the matrix metalloproteinase matrilysin.
J Biol Chem 269:2032–2040, 1994
4. BERNARDO MM, FRIDMAN R: TIMP-2 (tissue inhibitor of
metalloproteinases-2) regulates MMP-2 (matrix metalloproteinase-
2) activity in the extracellular environment after pro-MMP-2 acti-
vation by MT1 (membrane type 1)-MMP. Biochem J 374:739–745,
2003
5. NAGASE H, WOESSNER JF JR.: Matrix metalloproteinases. J Biol
Chem 274:21491–21494, 1999
6. EGEBLAD M, WERB Z: New functions for the matrix metallopro-
teinases in cancer progression. Nat Rev Cancer 2:161–174, 2002
7. MURPHY G, STANTON H, COWELL S, et al: Mechanisms for pro matrix
metalloproteinase activation. APMIS 107:38–44, 1999
8. BODE W, FERNANDEZ-CATALAN C, TSCHESCHE H, et al: Structural
properties of matrix metalloproteinases. Cell Mol Life Sci 55:639–
652, 1999
9. HARENDZA S, POLLOCK AS, MERTENS PR, et al: Tissue-specific
enhancer-promoter interactions regulate high level constitutive ex-
pression of matrix metalloproteinase 2 by glomerular mesangial
cells. J Biol Chem 270:18786–18796, 1995
10. TURCK J, POLLOCK AS, LEE LK, et al: Matrix metalloproteinase 2
(gelatinase A) regulates glomerular mesangial cell proliferation and
differentiation. J Biol Chem 271:15074–15083, 1996
11. LELONGT B, LELONGT B, PIEDAGNEL R, et al: Do matrix metallopro-
teinases MMP-2 and MMP-9 (gelatinases) play a role in renal devel-
opment, physiology and glomerular diseases? Curr Opin Nephrol
Hypertens 10:7–12, 2001
12. PARKS W C, MECHAM RP (editors): Matrix Metalloproteinases, San
Diego, Academic Press, 1998, pp 1–14
13. MARTIN J, EYNSTONE L, DAVIES M, et al: Induction of metallopro-
teinases by glomerular mesangial cells stimulated by proteins of the
extracellular matrix. J Am Soc Nephrol 12:88–96, 2001
14. KUGLER A: Matrix metalloproteinases and their inhibitors. Anti-
cancer Res 19:1589–1592, 1999
15. GOMIS-RUTH FX, MASKOS K, BETZ M, et al: Mechanism of inhibition
of the human matrix metalloproteinase stromelysin-1 by TIMP-1.
Nature 389:77–81, 1997
16. CHOW CC, MO KL, CHAN CK, et al: Renal Impairment in patients
with multiple myeloma. Hong Kong Med J 9:78–82, 2003
17. HERRERA GA: Renal manifestations of plasma cell dyscrasias: An
appraisal from the patient’s bedside to the research laboratory. An-
nals Diagn Pathol 4:174–200, 2000
18. HERRERA GA, RUSSELL WJ, ISAAC J, et al: Glomerulopathic light
chain—Mesangial cell interactions modulate in vitro extracellular
matrix remodeling and reproduce mesangiopathic findings docu-
mented in vivo. Ultrastruct Pathol 23:107–126, 1999
19. TENG J, RUSSELL WJ, GU X, et al: Different types of glomerulopathic
light chains interact with mesangial cells using a common receptor
but exhibit different intracellular trafficking patterns. Lab Invest
84:440–451, 2004
20. BELLOTTI V, MANGIONE P, MERLINI G: Review: immunoglobulin
light chain amyloidosis–the archetype of structural and pathogenic
variability. J Struct Biol 130:280–289, 2000
21. ABRAHAM RS, GEYER SM, PRICE-TROSKA TL, et al: Immunoglobu-
lin light chain variable (V) region genes influence clinical presenta-
tion and outcome in light chain–associated amyloidosis (AL). Blood
101:3801–3808, 2003
22. SOLOMON A, FRANGIONE B, FRANKLIN EC: kVI subgroup of human
light chains with amyloidosis AL. J Clin Invest 70:453–460, 1982
23. COMENZO RL, ZHANG Y, MARTINEZ C, et al: The tropism of organ
involvement in primary systemic amyloidosis: Contributions of Ig
VL germ line gene use and clonal plasma cell burden. Blood 98:714–
720, 2001
24. CHITI F, WEBSTER P, TADDEI N, et al: Designing conditions for in vitro
formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci
USA 96:3590–3594, 1999
25. COGNE M, SILVAIN C, KHAMLICHI AA, et al: Structurally abnormal
immunoglobulins in human immunoproliferative disorders. Blood
79:2181–2195, 1992
Keeling and Herrera: MMP and mesangial remodeling 1603
26. ABRAHAM RS, GEYER SM, PRICE-TROSKA TL, et al: Immunoglobu-
lin light chain variable (V) region genes influence clinical presenta-
tion and outcome in light chain-associated amyloidosis (AL). Blood
101:3801–3808, 2003
27. CHITI F, TADDEI N, BUCCIANTINI M, et al: Mutational analysis of the
propensity for amyloid formation by a globular protein. EMBO J
19:1441–1449, 2000
28. CHITI F, TADDEI N, BARONI F, et al: Kinetic partitioning of protein
folding and aggregation. Nat Struct Biol 9:137–143, 2002
29. CHITI F, STEFANI M, TADDEI N, et al: Rationalization of the ef-
fects of mutations on peptide and protein aggregation rates. Nature
424:805–808, 2003
30. HARPER PA, ROBINSON JM, HOOVER RL, et al: Improved methods
for culturing rat glomerular cells. Kidney Int 26:875–880, 1984
31. ISAAC J, KERBY JD, RUSSELL WJ, et al: In vitro modulation of
AL-amyloid formation by human mesangial cells exposed to amy-
loidogenic light chains. Amyloid Int J Exp Clin Invest 5:238–246,
1998
32. ZHU L, HERRERA GA, MURPHY-ULLRICH JE, et al: Pathogenesis of
glomerulosclerosis in light chain deposition disease: Role for trans-
forming growth factor-b . Am J Pathol 147:375–385, 1995
33. SHI S, COOTE RJ, TAYLOR CR: Antigen retrieval immunohistochem-
istry: Past, present, and future. J Histochem Cytochem 45:327–343,
1997
34. STANTON H, GAVRILOVIC J, ATKINSON SJ, et al: The activation of
ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is pro-
moted by culture on a fibronectin substrate and is concomitant with
an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form.
J Cell Sci 111:2789–2798, 1998
35. TURBAT-HERRERA EA, ISAAC J, SANDERS PW, et al: Integrated ex-
pression of glomerular extracellular matrix proteins and b 1 inte-
grins in monoclonal light chain-related renal diseases. Mod Pathol
10:485–495, 1997
36. SAITO K, SHIMIZU F, SATO T, et al: Modulation of human mesangial
cell behaviour by extracellular matrix components—The possible
role of interstitial type III collagen. Clin Exp Immunol 91:510–515,
1993
37. KEELING J, TENG J, HERRERA GA: AL-amyloidosis and light-chain
deposition disease light chains induce divergent phenotypic trans-
formations of human mesangial cells. Lab Invest 84:1322–1338,
2004
38. SCHNAPER HW, KLEINMAN HK: Regulation of cell function by ex-
tracellular matrix. Pediatr Nephrol 7:96–104, 1993
39. LOVETT DH, STERZEL RB, KASHGARIAN M, et al: Neutral proteinase
activity produced in vitro by cells of the glomerular mesangium.
Kidney Int 23:342–349, 1983
40. DAVIES M, MARTIN J, THOMAS GJ, et al: Proteinases and glomerular
matrix turnover. Kidney Int 41:671–678, 1992
41. CHENG S, LOVETT DH: GELATINASE A (MMP-2) is necessary and
sufficient for renal tubular cell epithelial-mesenchymal transforma-
tion. Am J Pathol 162:1937–1949, 2003
42. WANG M, QIN X, MUDGETT JS, et al: Matrix metalloproteinase de-
ficiencies affect contact hypersensitivity: stromelysin-1 deficiency
prevents the response and gelatinase B deficiency prolongs the re-
sponse. Proc Natl Acad Sci 96:6885–6889, 1999
43. MULLER D, ROESSNER A, ROCKEN C: Distribution pattern of ma-
trix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix
metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of
generalized AA- and AL amyloidosis. Virchows Arch 437:521–527,
2000
44. STIX B, KAHNE T, SLETTEN K, et al: Proteolysis of AA amyloid fib-
ril proteins by matrixmetalloproteinases-1, -2, and -3. Am J Pathol
159:561–570, 2001
45. MURRAY GI: Matrix metalloproteinases: a multifunctional group of
molecules. J Pathol 195:135–137, 2001
46. NAGASE H, WOESSNER JF JR.: Matrix metalloproteinases. J Biol
Chem 274:21491–21494, 1999
47. MIGNATTI P: Extracellular matrix remodeling by metalloproteinases
and plasminogen activators. Kidney Int 47:S12–S14, 1995
48. IMAI K, KUSAKABE M, SAKAKURA T, et al: Susceptibility of tenascin to
degradation by matrix metalloproteinases and serine proteinases.
FEBS Lett 352:216–218, 1994
49. TRUONG LD, PINDUR J, BARRIOS R, et al: Tenascin is an important
component of the glomerular extracellular matrix in normal and
pathologic conditions. Kidney Int 45:201–210, 1994
50. TRUONG LD, MAJESKY MW, PINDUR J: Tenascin is synthesized and
secreted by rat mesangial cells in culture and is present in extra-
cellular matrix in human glomerular diseases. J Am Soc Nephrol
4:1771–1777, 1994
51. KUHN C, MASON RJ: Immunolocalization of SPARC, tenascin, and
thrombospondin in pulmonary fibrosis. Am J Pathol 147:1759–1769,
1995
52. SAKAMURA T, KUSANO I: Tenascin in tissue perturbation repair. Acta
Pathol Jpn 41:247–258, 1991
53. ERICKSON HP, BOURDON MA: Tenascin: an extracellular matrix pro-
tein prominent in specialized embryonic tissues and tumors. Annu
Rev Cell Biol 5:71–92, 1989
54. ERICKSON HP: Tenascin-C, tenascin-R and tenascin-X: A family of
talented proteins in search of functions. Curr Opin Cell Biol 5:869–
876, 1993
55. TSUNODA T, INADA H, KALEMBEYI I, et al: Involvement of large
tenascin-C splice variants in breast cancer progression. Am J Pathol
162:1857–1867, 2003
56. KEELING J, DEMPSEY S, JOSEPH L, et al: The role of matrix metal-
loproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) in mesangial matrix replacement in AL-amyloidosis (AL-
Am): An-vivo and in-vitro correlative study, in Amyloid and Amy-
loidosis, edited by Grateau G, Kyle RA, Skinner M, Boca Raton,
CRC Press, 2005, pp 136–138
57. SOLOMON A, WEISS DT: Protein and host factors implicated in the
pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid:
Int J Exp Clin Invest 2:269–279, 1995
